Biovail news from FiercePharma
NewsGSK accused of monopolizing Wellbutrin
Did GlaxoSmithKline try to monopolize the Wellbutrin market? A lawsuit now certified as class-action says so. The plaintiffs accuse GSK of artificially boosting Wellbutrin prices by fibbing to the Read more...
New CEO expected to'strip' Biovail
To listen to news reports about incoming Biovail CEO Bill Wells, you'd think he was one of the horsemen of the Apocalypse. A director for three years, Wells is set to take over the helm May 1, and Read more...
SPOTLIGHT: Melnyk drops suit against Biovail
Biovail founder Eugene Melnyk (photo) has withdrawn his lawsuit against the company and its current CEO after the two Read more...
| Press ReleasesPRESS RELEASE: Biovail Confirms FDA Class 2 Status For BVF-033 Submission Biovail Confirms FDA Class 2 Status For BVF-033 Submission TORONTO -- Nov. 20, 2007--Biovail Corporation today confirmed that the U.S. Food and Drug Administration (FDA) has classified the response Read more... PRESS RELEASE: Biovail Enters Into License and Development AgreementBiovail Enters Into License and Development Agreement TORONTO -- Biovail Corporation today announced that a subsidiary, Biovail Laboratories International SRL, has entered into a license and Read more... |
Get more Biovail coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight